1Cerveri I,Corsico AG,Accordini S,et al. Underestimation of air- flow obstruction among young adults using FEVI/FVC<70% as a fixed cut-off:a longitudinal evaluation of clinical and functional outcomes[Jl. Thorax,2008,63: 1040-1045.
2Bestall JC,Paul EA,Garrod R,et al. Usefulness of the Medical Research Council(MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary diseases[J]. Tho- rax, 1999,54: 581-586.
3Jones PW, Harding G, Berry P,et al. Development and first vali- dation of the COPD Assessment Test[Jl. Eur Respir J,2009,34: 648-654.
4Donohue JF,Fogarty C,Lotvall J,et al. Once-daily bronchodila- tors for chronic obstructive pulmonary diseases:indacaterol versus tiotropium[J]. Am J Respir Crit Care Med,2010, 182:155-162.
5Ferguson GT,Calverley PM,Anderson JA,et al. Prevalence and progression of osteoporosis in patients with COPD : results from the Towards a Resolution in COPD Health study[J]. Chest, 2009,136: 1456-1465.
6Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symp- tomatic chronic obstructive pulmonary diseases: two randomized clinical trials [ J ]. Lancet, 2009,374 : 685-694.
7Sin DD,Anthonisen NR,Soriano JB,et al. Mortality in COPD: Role of comorbidities[J]. Eur Respir J,2006,28: 1245-1257.
7Li Q, Yao G, Zhu X. High -dose ambroxol reduces pulmonary complications in patients with acute cervical spinal cord injury after surgery[J]. Neurocrit Care, 2012,16(2) :267-272.
8Wang S, Huang D, Ma Q, et al. Does ambroxol confer a protective effect on the lungs in patients undergoing cardiac surgery or having lung resection [J] ? Interact Cardiovasc Thorae Surg, 2014,18(6) :830-834.
9Pfeifer S, Zissel G, Kienast K, et al. Reduction of cytokine release of blood and bronchoalveolar mononuclear cells by ambroxol[J]. Eur J Med Res, 1997, 2( 3) : 129-32.
10Seifart C, Clostermann U, Seifart U, et al. Cell-specific modulation of surfactant proteins by ambroxol treatment [J] . Toxicol Appl Pharmacol, 2005,203(1):27-35.
